论文部分内容阅读
[目的]探讨CD44v6、MUC1及VEGF在三阴性乳腺癌中的生物学特征及其对预后评估的意义。[方法]采用免疫组织化学SP法检测CD44v6、MUC1及VEGF在104例三阴性乳腺癌、168例非三阴性乳腺癌中的表达。[结果]CD44v6及MUC1在三阴及非三阴性乳腺癌中的表达无明显差异,VEGF在非三阴性乳腺癌的表达明显高于三阴性乳腺癌(P<0.05)。在三阴性乳腺癌中,CD44v6、MUC1及VEGF表达与年龄、组织学分级、肿瘤大小、临床分期、淋巴结转移均无明显相关性;在非三阴性乳腺癌中,除CD44v6在无淋巴结转移组表达明显高于转移组(P<0.05)外,CD44v6、MUC1及VEGF表达与其他临床病理参数均未见明显相关性。CD44v6、MUC1及VEGF联合检测,阳性率明显增加。但不同组合中三阴性乳腺癌及非三阴性乳腺癌的表达仍无差别。[结论]未发现CD44v6、MUC1及VEGF在三阴性乳腺癌中存在表达优势,且与预后参数如临床分期、组织学分级、淋巴结转移情况无明显相关性,其预后价值有待进一步验证。
[Objective] To investigate the biological characteristics of CD44v6, MUC1 and VEGF in triple-negative breast cancer and their significance for prognosis. [Method] Immunohistochemical SP method was used to detect the expression of CD44v6, MUC1 and VEGF in 104 cases of triple negative breast cancer and 168 cases of non - triple negative breast cancer. [Results] There was no significant difference in the expression of CD44v6 and MUC1 between the triple negative and non - triple negative breast cancers. The expression of VEGF in non - triple negative breast cancer was significantly higher than that in triple negative breast cancer (P <0.05). In triple-negative breast cancer, the expression of CD44v6, MUC1 and VEGF had no significant correlation with age, histological grade, tumor size, clinical stage and lymph node metastasis. In non-triple negative breast cancer, except CD44v6 expression in non-lymph node metastasis group (P <0.05), the expressions of CD44v6, MUC1 and VEGF were not significantly correlated with other clinicopathological parameters. CD44v6, MUC1 and VEGF combined detection, the positive rate was significantly increased. However, there was no difference in the expression of triple negative breast cancer and non-triple negative breast cancer in different combinations. [Conclusion] The positive expression of CD44v6, MUC1 and VEGF in triple negative breast cancer was not found, and there was no significant correlation with prognostic parameters such as clinical stage, histological grade and lymph node metastasis. The prognostic value of CD44v6, MUC1 and VEGF remains to be further verified.